Company CVAbout Suven Pharmaceuticals Ltd 
Suven Pharmaceuticals Ltd
Large Cap
Pharmaceuticals & Drugs
Suven Pharmaceuticals Limited (SPL) is a bio-pharmaceutical company, incorporated on 6th November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
Company Coordinates
No Company Details Available
Capital StructureCapital Structure
Present Equity Capital
INR 25.46 Cr
Number of Shares
25.46 Cr
Face Value
INR 1.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
25-Sep-2020
25.46
25.46
127282478
1
Bonus Issue
27-Jan-2020
12.73
12.73
127182478
1
Scheme of Arrangement
06-Nov-2018
1
0.01
100000
1
Subscriber to MOA
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 27 Schemes (13.15%)
FIIs
Held by 152 FIIs (10.84%)
Promoter with highest holding
Berhyanda Limited (50.1%)
Highest Public shareholder
Jasti Property And Equity Holdings Private Limited (9.9%)
Individual Investors Holdings
9.81%
Board of Directors
Management
Designation
Remuneration
Venkateswarlu Jasti
Managing Director
9.82 cr
Deepanwita Chattopadhyay
Independent Director
3.4 lacs
V Sambasiva Rao
Independent Director
3.8 lacs
Jerry Jeyasingh
Non-Exec & Non-Independent Dir
0
Hanumantha Rao Kokkonda
Company Secretary
0
D G Prasad
Independent Director
5.6 lacs
J V Ramudu
Chairman & Non Executive Dir.
6.0 lacs
Shweta Jalan
Non Executive Director
0
U B Pravin Rao
Independent Director
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
Raw Material Consumed
236.3739
0%
Raw Material Consumed
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
No Data Available for Finished Goods Segmentation
No Data Available
Stock DNARevenue and Profits:
Net Sales:
307 Cr
(Quarterly Results - Dec 2024)
Net Profit:
83 Cr
Pharmaceuticals & Drugs
INR 28,533 Cr (Large Cap)
96.00
33
0.00%
-0.31
12.29%
13.54
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
